Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Type 2 Diabetic Patients
100%
Placebo
100%
Insulin Analogues
100%
Insulin Therapy
100%
Metformin Therapy
100%
Copenhagen
100%
Metformin
100%
Carotid Intima-media Thickness (cIMT)
50%
Hemoglobin A1c (HbA1c)
50%
Insulin Dose
37%
Non-severe
25%
Change in Mean
25%
Insulin
25%
Serious Adverse Events
25%
Randomized Placebo-controlled Trial
12%
32 Factorial Design
12%
Large Reduction
12%
Between-group
12%
Investigator-initiated
12%
Weight Gain
12%
Twice Daily
12%
Between-group Difference
12%
Glycated Hemoglobin A1c
12%
Body Mass Index
12%
Denmark
12%
Number of Patients
12%
Hypoglycemic Episodes
12%
Subclinical Cardiovascular Disease
12%
Nursing and Health Professions
Patient with Type 2 Diabetes
100%
Non Insulin Dependent Diabetes Mellitus
100%
Placebo
100%
Metformin
100%
Hemoglobin A1c
55%
Arterial Wall Thickness
44%
Antidiabetic Agent
33%
Adverse Event
22%
Glycosylated Hemoglobin
11%
Insulin Treatment
11%
Body Mass
11%
Cardiovascular Disease
11%
Sample Size
11%
Factorial Design
11%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Patient with Type 2 Diabetes
100%
Placebo
100%
Glycon
100%
Hemoglobin A1c
55%
Intima-Media Thickness
44%
Antidiabetic Agent
33%
Adverse Event
22%
Cardiovascular Disease
11%
Insulin Treatment
11%
Body Mass Index
11%
Glycated Hemoglobin
11%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Metformin
100%
Non Insulin Dependent Diabetes Mellitus
100%
Insulin Analog
100%
Hemoglobin A1c
55%
Antidiabetic Agent
33%
Adverse Event
22%
Cardiovascular Disease
11%
Glycosylated Hemoglobin
11%
Biochemistry, Genetics and Molecular Biology
Insulin Analog
100%
Glycated Hemoglobin
50%
Body Mass
50%
Sample Size
50%
Food Science
Insulin
100%
Glycosylated Hemoglobin
11%